Disease Landscape and Forecast Insights

Market Outlook Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, presents as hives that persist daily or almost daily for six weeks or longer without an obvious…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The EGFR and ALK TKIs Tagrisso and…

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include…

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in…

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) market. Most inpatients are successfully treated empirically with such agents, making it difficult for…

Hemophilia treatment is gradually consuming more U.S. payer budget dollars. The increasing cost of factor concentrate and the growing preference for prophylaxis treatment are key factors driving…

MARKET OUTLOOK Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are among the most common and serious infections in the hospital setting. HABP/…

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…

No disease-modifying therapies are approved to treat primary Sjögren’s syndrome (pSS), a progressive, autoimmune disease characterized by sicca symptoms, which are caused by chronic inflammation…